NCT00451152
Completed
Phase 2
A Study of the Safety and IOP-Lowering Efficacy of Anecortave Acetate in Patients With Open-Angle Glaucoma
ConditionsOpen-angle Glaucoma
Overview
- Phase
- Phase 2
- Intervention
- Anecortave Acetate Sterile Suspension, 30 mg/mL
- Conditions
- Open-angle Glaucoma
- Sponsor
- Alcon Research
- Enrollment
- 89
- Locations
- 1
- Primary Endpoint
- Mean Intraocular Pressure (IOP)
- Status
- Completed
- Last Updated
- 13 years ago
Overview
Brief Summary
The purpose of this study was to evaluate the safety and intraocular pressure (IOP)-lowering efficacy of anecortave acetate for treatment of elevated IOP in patients with open-angle glaucoma.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Diagnosis of open-angle glaucoma;
- •Other protocol-defined inclusion criteria may apply.
Exclusion Criteria
- •Pseudoexfoliation;
- •Pigment dispersion component;
- •Other protocol-defined exclusion criteria may apply.
Arms & Interventions
Anecortave Acetate Depot
Intervention: Anecortave Acetate Sterile Suspension, 30 mg/mL
Anecortave Acetate Vehicle
Intervention: Anecortave Acetate Vehicle
Outcomes
Primary Outcomes
Mean Intraocular Pressure (IOP)
Time Frame: 3 months
Secondary Outcomes
- Percent Treatment Failures(3 months)
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 2
Safety and Intraocular Pressure (IOP)-Lowering Efficacy of AL-39256 in Patients With Open-Angle Glaucoma or Ocular HypertensionOpen-Angle GlaucomaOcular HypertensionNCT00761709Alcon Research104
Unknown
Phase 2
Intraocular Pressure (IOP) Lowering Efficacy of Transdermal Brimonidine TherapyGlaucomaNCT01345448Nanduri, Padma, M.D., FACS22
Completed
Phase 2
Anecortave Acetate Safety in Patients With Open-Angle Glaucoma or Ocular HypertensionOpen-angle GlaucomaOular HypertensionNCT00691717Alcon Research201
Completed
Not Applicable
Investigation of the iStent Inject® Devices in Open-Angle GlaucomaGlaucoma, Open-AngleNCT03624699Dr. Kaweh Mansouri42
Unknown
Phase 2
Intraocular Pressure (IOP) Lowering Efficacy of Transdermal Latanoprost TherapyGlaucomaNCT01426464Nanduri, Padma, M.D., FACS22